Nano-Oncology Targeting the Lactate-MCT1/MCT4-Histone Lactylation Axis: A New Hallmark-Based Strategy Against Metastatic Cancer Progression

Metastatic progression remains the principal cause of cancer-related mortality because disseminating tumor cells acquire interlocking metabolic, epigenetic, stromal and immune-adaptive programs that are insufficiently controlled by conventional cytotoxic and single-target molecular therapies. Among these programs, lactate has evolved from a metabolic waste product into a multifunctional oncometabolite that coordinates extracellular acidosis, nutrient sharing, angiogenic adaptation, invasion, immune paralysis and chromatin remodeling. The monocarboxylate transporters MCT1 and MCT4 create the transport infrastructure for this biology: MCT4 supports lactate efflux from hypoxic glycolytic cancer cells and cancer-associated fibroblasts, whereas MCT1 enables lactate import into oxidative tumor cells, endothelial cells and stromal compartments capable of using lactate as a fuel and signaling substrate. In parallel, histone lactylation has emerged as a metabolism-to-chromatin interface through which lactate abundance can reshape transcriptional outputs that favor epithelial-mesenchymal transition, stemness, inflammatory reprogramming, macrophage polarization, immune escape and metastatic niche conditioning. This review proposes a hallmark-based nano-oncology strategy that treats the lactate-MCT1/MCT4-histone lactylation axis as a druggable metastatic control circuit rather than as an isolated metabolic abnormality. We critically integrate quantitative features of tumor lactate accumulation, transporter polarity, acidic pH, epigenetic lactylation, therapeutic vulnerabilities and nanoparticle design principles. We further outline nanoformulation architectures capable of simultaneously modulating lactate production, lactate transport, chromatin lactylation and downstream pro-metastatic phenotypes using ligand-directed, pH/redox-responsive and immune-compatible delivery systems. Finally, we present a biomarker-guided preclinical and clinical translation framework for axis validation, patient selection and combination therapy. The central argument is that metastatic cancer progression may be more effectively restrained by spatially coordinated nanomedicine that disrupts metabolic communication and epigenetic memory within the tumor ecosystem than by non-selective metabolic inhibition alone